According to the NCI website, perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity.

Indikationen/Anwendungsmöglichkeiten gemäss EMEA:

On 10 June 2010, orphan designation (EU/3/10/740) was granted by the European Commission to Æterna Zentaris GmbH, Germany, for perifosine for the treatment of multiple myeloma.

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to National Cancer Institute
Link zu Wiki
Link to European Medicines Agency (EMEA)